Long-term effect of neoadjuvant denosumab treatment in high-risk early breast cancer (GeparX).

ESMO Open · 2025 · PMC12702335 · PMID 41313969

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Notably, TNBC patients under the nPac weekly regimen showed a trend for a better iDFS in the landmark analysis at year 5, particularly those without pCR.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.